Stock GLMD GALMED PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Galmed Pharmaceuticals Ltd. Share Price

Equities

GLMD

IL0011313900

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:00 27/04/2024 am IST 		5-day change 1st Jan Change
0.3916 USD -0.23% Intraday chart for Galmed Pharmaceuticals Ltd. +5.04% -13.93%
04/04 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
15/03 Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 2.35M 196M
Net income 2024 * -10M -834M Net income 2025 * -14M -1.17B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.3 x
P/E ratio 2025 *
-0.38 x
Employees 6
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.13%
More Fundamentals * Assessed data

Chart Galmed Pharmaceuticals Ltd.

Dynamic Chart

Latest news about Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study MT
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4 MT
Top Midday Decliners MT
Galmed Pharmaceuticals Prices $7 Million Securities Offering; Shares Slump MT
Top Premarket Decliners MT
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Galmed Pharmaceuticals Ltd. Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis CI
More news

Analyst Recommendations on Galmed Pharmaceuticals Ltd.

Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4 MT
Maxim Group Downgrades Galmed Pharmaceuticals to Hold From Buy MT
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1 From $5 MT
Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $0.70 From $5 MT
Galmed Pharmaceuticals Shares Fall After Rating Downgrade From Raymond James MT
More recommendations

Press releases Galmed Pharmaceuticals Ltd.

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis PR
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K PU
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study PR
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification AQ
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR
More press releases

Quotes and Performance

1 day-0.23%
1 week+5.04%
Current month+13.08%
1 month+22.30%
3 months+3.46%
6 months+5.81%
Current year-13.93%
More quotes

Highs and lows

1 week
0.35
Extreme 0.35
0.40
1 month
0.32
Extreme 0.315
0.44
Current year
0.30
Extreme 0.3
0.47
1 year
0.26
Extreme 0.26
7.80
3 years
0.26
Extreme 0.26
61.20
5 years
0.26
Extreme 0.26
127.58
10 years
0.26
Extreme 0.26
405.90
More quotes

Managers and Directors - Galmed Pharmaceuticals Ltd.

Managers TitleAgeSince
Allen Baharaff CEO
 Chief Executive Officer 59 01/00/01
Doron Cohen DFI
 Director of Finance/CFO 57 01/22/01
Guy Nehemya COO
 Chief Operating Officer 39 01/13/01
Members of the board TitleAgeSince
David Sidransky BRD
 Director/Board Member 64 01/14/01
Carol Brosgart BRD
 Director/Board Member 72 07/17/07
Allen Baharaff CEO
 Chief Executive Officer 59 01/00/01
More insiders

Quotes

Date Price Change Volume
26/24/26 0.3916 -0.23% 27,223
25/24/25 0.3925 -1.88% 35,002
24/24/24 0.4 +10.68% 51,649
23/24/23 0.3614 -0.74% 66,362
22/24/22 0.3641 -2.33% 64,303

Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST

More quotes

Company Profile

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Sector
Biotechnology & Medical Research
Calendar
08/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3916 USD
Average target price
1 USD
Spread / Average Target
+155.36%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GALMED PHARMACEUTICALS LTD. Stock Galmed Pharmaceuticals Ltd.
-13.93% 2.35M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GLMD Stock